Effect of Valsartan on Angiotensin II- and Vasopressin-Degrading Activities in the Kidney of Normotensive and Hypertensive Rats

Valsartan, a selective antagonist of angiotensin II at the AT₁ receptor subtype, is an efficacious, orally active, blood pressure-lowering agent used in hypertensive patients. Given that aminopeptidases (APs) play a major role in the metabolism of local peptides involved in blood pressure control, studying them helped us to understand cardiovascular control. We studied the effect of valsartan on angiotensin II- (GluAP) and vasopressin- (CysAP) degrading activities in the kidney in the rat model of renovascular hypertension, Goldblatt two-kidney one-clip. GluAP and CysAP in renal cortex and medulla exhibited different responses to hypertension and valsartan treatment. In the renal cortex, GluAP decreased in clipped and non-clipped kidneys of hypertensive animals. However, while hypertension did not affect GluAP in the clipped kidney medulla, the non-clipped kidney exhibited an increase in soluble and a decrease in membrane-bound activity. Valsartan decreased soluble GluAP in the medulla of normotensive and hypertensive animals. In the renal cortex, CysAP activity was mainly downregulated following hypertension. Valsartan decreased soluble CysAP activity in sham-operated, but not in hypertensive animals. The renal medulla showed a significant valsartan-related decreased activity in clipped and non-clipped kidneys of both sham-operated and hypertensive animals. These results suggest a functional relationship between the AT₁ receptor and vasopressin-degrading activity.

Key words:

Glutamyl Aminopeptidase - Cystinyl Aminopeptidase - Kidney - Renovascular Hypertension - Valsartan

References

• 1 Criscione L, Bradley W A, Bühlmayer P, Whitebread S, Glazer R, Lloyd P, Mueller P, de Gasparo M. Valsartan: Preclinical and clinical profile of an antihypertensive angiotensin-II antagonist.  Card Drug Rev. 1995;  13 230-250
• 2 Said S I. Neuropeptides in blood pressure control. In: Laragh JH, Brenner BM (eds). Hypertension: pathophysiology, diagnosis and management.  New York:; Raven Press, 1990: 791-803
• 3 Martinez J M, Prieto I, Ramirez M J, de Gasparo M, Hermoso F, Arias J M, Alba F, Ramirez M. Sex differences and age-related changes in human serum aminopeptidase A activity.  Clin Chim Acta. 1998;  274 53-61
• 4 Song L, Healy D P. Kidney aminopeptidase A and hypertension, part II. Effects of angiotensin II.  Hypertension. 1999;  33 746-752
• 5 Song L, Ye M, Troyanovskaya M, Wilk E, Wilk S, Healy D P. Rat kidney glutamyl aminopeptidase (aminopeptidase A): molecular identity and cellular localization.  Am J Physiol. 1994;  267 F546-F557
• 6 Itoh C, Nagamatsu A. An aminopeptidase activity from porcine kidney that hydrolyzes oxytocin and vasopressin: purification and partial characterization.  Biochim Biophys Acta. 1995;  1243 203-208
• 7 Prieto I, Martinez A, Martinez J M, Ramirez M J, Vargas F, Alba F, Ramírez M. Activities of aminopeptidases in a rat saline model of volume hypertension.  Horm Metab Res. 1998;  30 246-248
• 8 Gonzalez C B, Herrera V L, Ruiz-Opazo N. Renal immunocytochemical distribution and pharmacological properties of the dual angiotensin II/AVP receptor.  Hypertension. 1997;  29 957-961
• 9 Ramírez M, Prieto I, Martinez J M, Vargas F, Alba F. Renal aminopeptidase activities in animal models of hypertension.  Regul Peptides. 1997;  72 155-159
• 10 Müller P, Flesch G, de Gasparo M, Gasparini M, Howald H. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects.  Eur J Pharmacol. 1997;  52 441-449
• 11 Bindschedler M, Degen P, Flesh G, de Gasparo M, Preiswerk G. Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide.  Eur J Clin Pharmacol. 1997;  52 371-378
• 12 Martinez-Maldonado M. Pathophysiology of renovascular hypertension.  Hypertension. 1991;  17 707-719
• 13 Wang Z Q, Millatt L J, Heiderstadt N T, Siragy H M, Johns R A, Carey R M. Differential regulation of renal angiotensin subtype AT1A and AT2 receptor protein in rats with angiotensin-dependent hypertension.  Hypertension. 1999;  33 96-101
• 14 Larivière R, St-Louis J, Schiffrin E L. Vascular vasopressin receptors in renal hypertensive rats.  Am J Physiol. 1988;  255 H693-H698
• 15 Siragy H M, de Gasparo M, Carey R M. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats.  Hypertension. 2000;  35 1074-1077